These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10063918)

  • 1. Glucagonlike peptide-1 (GLP-1) participation in ileal brake induced by intraluminal peptones in rat.
    Giralt M; Vergara P
    Dig Dis Sci; 1999 Feb; 44(2):322-9. PubMed ID: 10063918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sympathetic pathways mediate GLP-1 actions in the gastrointestinal tract of the rat.
    Giralt M; Vergara P
    Regul Pept; 1998 Apr; 74(1):19-25. PubMed ID: 9657354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans.
    Schirra J; Nicolaus M; Roggel R; Katschinski M; Storr M; Woerle HJ; Göke B
    Gut; 2006 Feb; 55(2):243-51. PubMed ID: 15985560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans.
    Schirra J; Houck P; Wank U; Arnold R; Göke B; Katschinski M
    Gut; 2000 May; 46(5):622-31. PubMed ID: 10764704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1 secretion is enhanced directly in the ileum but indirectly in the duodenum by a newly identified potent stimulator, zein hydrolysate, in rats.
    Hira T; Mochida T; Miyashita K; Hara H
    Am J Physiol Gastrointest Liver Physiol; 2009 Oct; 297(4):G663-71. PubMed ID: 19661152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PYY and GLP-1 contribute to feedback inhibition from the canine ileum and colon.
    Wen J; Phillips SF; Sarr MG; Kost LJ; Holst JJ
    Am J Physiol; 1995 Dec; 269(6 Pt 1):G945-52. PubMed ID: 8572226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide (GLP-1) is involved in the central modulation of fecal output in rats.
    Gülpinar MA; Bozkurt A; Coşkun T; Ulusoy NB; Yegen BC
    Am J Physiol Gastrointest Liver Physiol; 2000 Jun; 278(6):G924-9. PubMed ID: 10859222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intraduodenal fatty acids on appetite, antropyloroduodenal motility, and plasma CCK and GLP-1 in humans vary with their chain length.
    Feltrin KL; Little TJ; Meyer JH; Horowitz M; Smout AJ; Wishart J; Pilichiewicz AN; Rades T; Chapman IM; Feinle-Bisset C
    Am J Physiol Regul Integr Comp Physiol; 2004 Sep; 287(3):R524-33. PubMed ID: 15166004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1 regulates gastroduodenal motility involving cholinergic pathways.
    Schirra J; Nicolaus M; Woerle HJ; Struckmeier C; Katschinski M; Göke B
    Neurogastroenterol Motil; 2009 Jun; 21(6):609-18, e21-2. PubMed ID: 19220754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-Like Peptide-1 Inhibits Prandial Gastrointestinal Motility Through Myenteric Neuronal Mechanisms in Humans.
    Halim MA; Degerblad M; Sundbom M; Karlbom U; Holst JJ; Webb DL; Hellström PM
    J Clin Endocrinol Metab; 2018 Feb; 103(2):575-585. PubMed ID: 29177486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mechanism of the serotonin effect on motility of the duodenum, ileum, and jejunum in awake rabbits].
    Ovsiannikov VI; Berezina TP
    Ross Fiziol Zh Im I M Sechenova; 2002 Aug; 88(8):1017-27. PubMed ID: 12503449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local, exendin-(9-39)-insensitive, site of action of GLP-1 in canine ileum.
    Daniel EE; Anvari M; Fox-Threlkeld JE; McDonald TJ
    Am J Physiol Gastrointest Liver Physiol; 2002 Sep; 283(3):G595-602. PubMed ID: 12181172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
    Kolligs F; Fehmann HC; Göke R; Göke B
    Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-1 is a physiological incretin in rat.
    Wang Z; Wang RM; Owji AA; Smith DM; Ghatei MA; Bloom SR
    J Clin Invest; 1995 Jan; 95(1):417-21. PubMed ID: 7814643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1-(7-36) amide and peptide YY mediate intraduodenal fat-induced inhibition of acid secretion in dogs.
    Fung LC; Chisholm C; Greenberg GR
    Endocrinology; 1998 Jan; 139(1):189-94. PubMed ID: 9421414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans.
    Layer P; Holst JJ; Grandt D; Goebell H
    Dig Dis Sci; 1995 May; 40(5):1074-82. PubMed ID: 7729267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-related effects of lauric acid on antropyloroduodenal motility, gastrointestinal hormone release, appetite, and energy intake in healthy men.
    Little TJ; Feltrin KL; Horowitz M; Smout AJ; Rades T; Meyer JH; Pilichiewicz AN; Wishart J; Feinle-Bisset C
    Am J Physiol Regul Integr Comp Physiol; 2005 Oct; 289(4):R1090-8. PubMed ID: 15961531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral and central administration of exogenous urocortin 1 disrupts the fasted motility pattern of the small intestine in rats via the corticotrophin releasing factor receptor 2 and a cholinergic mechanism.
    Yin Y; Dong L; Yin D
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e79-87. PubMed ID: 17944898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin.
    Tolessa T; Gutniak M; Holst JJ; Efendic S; Hellström PM
    J Clin Invest; 1998 Aug; 102(4):764-74. PubMed ID: 9710445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome.
    Hellström PM; Näslund E; Edholm T; Schmidt PT; Kristensen J; Theodorsson E; Holst JJ; Efendic S
    Neurogastroenterol Motil; 2008 Jun; 20(6):649-59. PubMed ID: 18298441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.